ACC017+FTC/TAF

PreclinicalSmall molecule

JJiangsu Aidea Pharmaceutical Group Co., Ltd.

ACC017+FTC/TAF is one of 2 small molecule programs targeting Infection, Human Immunodeficiency Virus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Infection, Human Immunodeficiency VirusCompleted

Infection, Human Immunodeficiency VirusPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Infection, Human Immunodeficiency Virus

#DrugCompanyPhaseTrials

CAB LA

GSK

Phase 3

1 2

ACC017+FTC/TAF

JJiangsu Aidea Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Infection, Human Immunodeficiency Virus

NCT07711223

Clinical

Trials by Indication[1]

Infection, Human Immunodeficiency Virus2 trials

A Phase Ib/IIa, Randomized, Double Blinded, Perallel, Dosing Ranging, Placebo Controled and Proof of Concept Clinical Trial to Evaluate the Safety, Tolerability, PK and Antiviral Effect of ACC017 Tablet as Monotherapy/Combination With NRTI in Treatment naïve HIV-infected Adults

Completed·JJiangsu Aidea Pharmaceutical Group Co., Ltd.·Preclinical·NCT06719310·36 enrolled

A Multicenter, Randomized, Double-Blind, Double-Dummy, Dolutegravir Sodium Tablets Controlled, Phase III Study to Evaluate the Efficacy and Safety of ACC017 Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)

Recruiting·JJiangsu Aidea Pharmaceutical Group Co., Ltd.·Preclinical·NCT07711223·660 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ACC017+FTC/TAF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACC017+FTC/TAF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACC017+FTC/TAF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Aidea Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJiangsu Aidea Pharmaceutical Group Co., Ltd.

ACC017+FTC/TAF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Infection, Human Immunodeficiency Virus2 trials

References

Drug Info

Quick Facts

Related News